JP2024515618A5 - - Google Patents

Info

Publication number
JP2024515618A5
JP2024515618A5 JP2023562813A JP2023562813A JP2024515618A5 JP 2024515618 A5 JP2024515618 A5 JP 2024515618A5 JP 2023562813 A JP2023562813 A JP 2023562813A JP 2023562813 A JP2023562813 A JP 2023562813A JP 2024515618 A5 JP2024515618 A5 JP 2024515618A5
Authority
JP
Japan
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562813A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515618A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/086870 external-priority patent/WO2022218383A1/zh
Publication of JP2024515618A publication Critical patent/JP2024515618A/ja
Publication of JP2024515618A5 publication Critical patent/JP2024515618A5/ja
Pending legal-status Critical Current

Links

JP2023562813A 2021-04-14 2022-04-14 抗腫瘍処置における抗体の使用 Pending JP2024515618A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110404963 2021-04-14
CN202110404963.8 2021-04-14
PCT/CN2022/086870 WO2022218383A1 (zh) 2021-04-14 2022-04-14 抗体在抗肿瘤治疗中的用途

Publications (2)

Publication Number Publication Date
JP2024515618A JP2024515618A (ja) 2024-04-10
JP2024515618A5 true JP2024515618A5 (https=) 2025-04-22

Family

ID=83574345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562813A Pending JP2024515618A (ja) 2021-04-14 2022-04-14 抗腫瘍処置における抗体の使用

Country Status (13)

Country Link
US (1) US20240199741A1 (https=)
EP (1) EP4324854A4 (https=)
JP (1) JP2024515618A (https=)
KR (1) KR20230171456A (https=)
CN (2) CN120346314A (https=)
AU (1) AU2022258365A1 (https=)
BR (1) BR112023021177A2 (https=)
CA (1) CA3213734A1 (https=)
IL (1) IL307494A (https=)
MX (1) MX2023012182A (https=)
PH (1) PH12023552750A1 (https=)
WO (1) WO2022218383A1 (https=)
ZA (1) ZA202309812B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022002028A2 (pt) * 2019-08-02 2022-04-12 Cttq Akeso Shanghai Biomed Tech Co Ltd Anticorpo anti-pd-1 e uso farmacêutico do mesmo
CN115845050A (zh) * 2022-12-28 2023-03-28 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗食管鳞癌患者的药物中的用途
JP2026507907A (ja) * 2023-03-07 2026-03-06 アケソ・ファーマ・カンパニー,リミテッド 抗ctla4抗pd-1二重特異性抗体を含有する医薬組成物とその使用
CN118562008B (zh) * 2024-05-15 2025-06-03 复旦大学 一种靶向her2的纳米单克隆抗体及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974253A (zh) * 2014-04-01 2015-10-14 上海中信国健药业股份有限公司 抗ctla-4/pd-1双特异性抗体、其制备方法及应用
CN106188296B (zh) * 2016-07-19 2018-05-08 康融东方(广东)医药有限公司 一类抗血管内皮生长因子受体vegfr2的单克隆抗体及其编码基因和应用
CN106967172B (zh) 2016-08-23 2019-01-08 康方药业有限公司 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途
WO2018183408A1 (en) * 2017-03-31 2018-10-04 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody
AU2018393111B2 (en) * 2017-12-21 2025-07-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
WO2019179421A1 (en) * 2018-03-19 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific pd-1/ctla-4 antibody molecules
CN109053895B (zh) * 2018-08-30 2020-06-09 中山康方生物医药有限公司 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
WO2020185722A2 (en) * 2019-03-13 2020-09-17 Merck Sharp & Dohme Corp. Anti-cancer combination therapies comprising ctla-4 and pd-1 blocking agents
WO2021023117A1 (zh) * 2019-08-02 2021-02-11 康方药业有限公司 抗ctla4-抗pd-1双特异性抗体及其用途

Similar Documents

Publication Publication Date Title
JP2024515618A5 (https=)
JP2023504003A5 (https=)
JP2025102836A5 (https=)
IL293241A (en) Bispecific antibody, anti-1-pd, anti-vegfa, pharmaceutical preparation containing it and its use
JP2024509018A5 (https=)
JP2024515396A5 (https=)
JP2022542450A5 (https=)
FI3802608T3 (fi) Cd3-vasta-aineita ja niiden käyttötapoja
JP2021515559A5 (https=)
JP2018534933A5 (https=)
JP2020534351A5 (https=)
JP2017522871A5 (https=)
JP2025506318A5 (https=)
RU2018124319A (ru) Новые антитела к клаудину и способы их применения
CN113302207A (zh) Cd38和icam1抗体及其用途
JP2022525071A5 (https=)
JP2022522344A5 (https=)
JP2024538669A5 (https=)
US20240199741A1 (en) Use of antibody in anti-tumor treatment
JP2024525916A5 (https=)
JP2025520232A5 (https=)
JP2025504496A5 (https=)
JP2023506158A5 (https=)
RU2024125768A (ru) Фармацевтическая композиция, содержащая биспецифическое антитело против ctla4-против pd-1 и чиаураниб
RU2024116190A (ru) Антитело против cd73 и его применение